<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Bendalis</title>
	<atom:link href="https://bendalis.com/en/feed/" rel="self" type="application/rss+xml" />
	<link>https://bendalis.com/en</link>
	<description>Your specialist for sterile products in the hospital sector</description>
	<lastbuilddate>Sunday, 10 May 2026 06:50:58 +0000</lastbuilddate>
	<language>en-GB</language>
	<sy:updateperiod>
	per hour	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bendalis.com/site/wp-content/uploads/logo.svg</url>
	<title>Bendalis</title>
	<link>https://bendalis.com/en</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Vancomycin available again – Bendalis ensures supply</title>
		<link>https://bendalis.com/en/vancomycin-available-again-bendalis-ensures-supply/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Sun, 01 Mar 2026 15:34:40 +0000</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">http://draft.bendalis.com/?p=3034</guid>

					<description><![CDATA[We are pleased to inform our customers and partners that Vancomycin Bendalis is once again available in both strengths (500 mg and 1000 mg). Packs of 10 of both variants will be ready for dispatch from 1 March 2026. The renewed availability is the result of intensive work on new production capacities: Bendalis has successfully integrated an additional manufacturing facility in Spain into the […]]]></description>
		
		
		
			</item>
		<item>
		<title>5FU available again – secure supply through Bendalis</title>
		<link>https://bendalis.com/en/5-fu-is-available-again-ensuring-a-secure-supply-through-bendalis/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Sunday, 1 March 2026 15:33:00 GMT</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">http://draft.bendalis.com/?p=3032</guid>

					<description><![CDATA[We are pleased to inform our customers and partners that 5Fluorouracil (5FU) is available again with immediate effect. Through our consistent work on a stable, resilient supply chain and close coordination with the responsible authorities, the supply situation has been successfully secured. The recently granted approval of the corresponding variation by the BfArM confirms the quality and reliability of our […]]]></description>
		
		
		
			</item>
		<item>
		<title>Stronger together: Bendalis to take over Sugammadex along with worldwide distribution rights</title>
		<link>https://bendalis.com/en/together-stronger-bendalis-acquires-sugammadex-with-worldwide-distribution-rights/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Wed, 01 Jan 2025 15:32:00 GMT</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">http://draft.bendalis.com/?p=3030</guid>

					<description><![CDATA[As of 1 January 2025, Bendalis GmbH has acquired the product Sugammadex in its entirety, including all global distribution rights, from Biofactor GmbH. This step marks a significant expansion of our international activities and creates clear, reliable, and long-term prospects for our partners and customers. With the acquisition, all existing customer relationships, contractual rights, and all relevant distribution structures […]]]></description>
		
		
		
			</item>
		<item>
		<title>Somatostatin Lyomark 3 mg: Distribution Partnership with Inresa Arzneimittel</title>
		<link>https://bendalis.com/en/somatostatin-lyomark-3-mg_inresa_bendalis/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Fri, 08 Dec 2023 10:18:00 +0000</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Bendalis]]></category>
		<category><![CDATA[Bendalis GmbH]]></category>
		<category><![CDATA[Inresa]]></category>
		<category><![CDATA[Somatostatin]]></category>
		<category><![CDATA[Somatostatin 3mg]]></category>
		<category><![CDATA[Somatostatin acetat]]></category>
		<category><![CDATA[Somatostatin Lyomark 3mg]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=2156</guid>

					<description><![CDATA[Oberhaching, December 2023 Bendalis GmbH and Inresa Arzneimittel GmbH today announce their new distribution partnership for Somatostatin Lyomark 3 mg. Through this partnership, Inresa will be the sales and distribution partner for the product. Inresa was chosen as a strategic distributor to continue meeting the demand for Somatostatin and ensure patient care. Furthermore, Inresa is […]]]></description>
		
		
		
			</item>
		<item>
		<title>Changes in Management at Bendalis GmbH and Lyomark Pharma GmbH</title>
		<link>https://bendalis.com/en/changes-in-management-at-bendalis-gmbh-and-lyomark-pharma-gmbh-2/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Mon, 11 Apr 2022 08:32:46 +0000</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=2072</guid>

					<description><![CDATA[Oberhaching, April 2022

Dear Sir or Madam,

Today, we are informing you about a change in personnel at Bendalis GmbH and Lyomark Pharma GmbH. Mr. Parvany will be leaving the companies on 31 March 2022. Mr. Parvany has been active in both companies since 2012, initially as Head of Sales and Marketing and since 2017 as Managing Director. […]]]></description>
		
		
		
			</item>
		<item>
		<title>Changes in Management at Bendalis GmbH and Lyomark Pharma GmbH</title>
		<link>https://bendalis.com/en/changes-in-management-at-bendalis-gmbh-and-lyomark-pharma-gmbh/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Tue, 21 Sep 2021 14:37:57 +0000</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=2045</guid>

					<description><![CDATA[Oberhaching, 21.09.2021

Dear Sir or Madam,

Today we wish to inform you about a change in personnel at Bendalis GmbH and Lyomark Pharma GmbH. Mr Malocho will be leaving the companies on 30.09.2021. Mr Malocho has been working at both companies since 2006, initially as Head of Supply Chain and since 2014 as Managing Director. We would like to thank you [...]]]></description>
		
		
		
			</item>
		<item>
		<title>Inceptua and Bendalis enter into an exclusive agreement for clinical trials of oncology drugs</title>
		<link>https://bendalis.com/en/inceptua-and-bendalis-sign-exclusive-contract-for-oncology-drugs/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Mon, 25 Nov 2019 14:00:48 +0000</pubdate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Bendalis GmbH]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Inceptua]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=1940</guid>

					<description><![CDATA[BERLIN / MUNICH – 25 November 2019 – Inceptua Group (formerly Multipharma GmbH), a global pharmaceutical company and service partner, and Bendalis GmbH, a German manufacturer of generic oncology products and specialised therapeutics, today announced the signing of an exclusive agreement for the supply of clinical trial materials for generic oncology products. This agreement will make Inceptua the exclusive distribution partner for the products of […]]]></description>
		
		
		
			</item>
		<item>
		<title>Thank you for visiting CPhI Frankfurt</title>
		<link>https://bendalis.com/en/thank-you-for-your-visit-to-cphi-frankfurt/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Wed, 13 Nov 2019 11:30:20 +0000</pubdate>
				<category><![CDATA[Veranstaltungen]]></category>
		<category><![CDATA[Bendalis]]></category>
		<category><![CDATA[CPhI]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=1906</guid>

					<description><![CDATA[We would like to thank all our partners and interested parties for the many stimulating discussions during CPhI in Frankfurt. We hope your days in Frankfurt were as successful as ours. We look forward to seeing you all again next year from 13 – 15 October in Milan. Your Bendalis Team]]></description>
		
		
		
			</item>
		<item>
		<title>Visit us at CPhI in Frankfurt from 5th to 7th November 2019</title>
		<link>https://bendalis.com/en/meet-us-from-5-to-7-november-2019-at-cphi-frankfurt/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Thu, 05 Sep 2019 11:12:06 +0000</pubdate>
				<category><![CDATA[Veranstaltungen]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=1889</guid>

					<description><![CDATA[This year, Bendalis GmbH will once again have its own stand at the CPhI trade fair from 5th to 7th November in Frankfurt. We would be delighted to welcome you to our stand 92F23. Your Bendalis Team]]></description>
		
		
		
			</item>
		<item>
		<title>Join us from 9th to 11th October 2018 at CPhI in Madrid</title>
		<link>https://bendalis.com/en/meet-us-from-9-to-11-october-2018-at-cphi-in-madrid/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubdate>Fri, 13 Jul 2018 10:30:58 +0000</pubdate>
				<category><![CDATA[Veranstaltungen]]></category>
		<guid ispermalink="false">https://bendalis.com/?p=1806</guid>

					<description><![CDATA[This year, Bendalis GmbH will once again be present at the CPhI trade fair from October 9th to 11th in Madrid. You can find us, along with our sister company Lyomark Pharma GmbH, here: Lyomark Pharma Stand 14.1 D92. We would be delighted to welcome you to our stand (14.1.D92). Your Lyomark Bendalis Team]]></description>
		
		
		
			</item>
	</channel>
</rss>